Cargando…

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy

SIMPLE SUMMARY: Recently, high-risk prostate cancer was subdivided to a very-high-risk group considered to have the worst prognosis, including clinical stage T3b–T4, primary Gleason pattern 5, or more than four biopsy cores with Gleason score 8–10. Among these, T3b–T4 stage is a special interest in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Hideya, Suzuki, Gen, Masui, Koji, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Yoshida, Ken, Nakamura, Satoaki, Okabe, Haruumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070084/
https://www.ncbi.nlm.nih.gov/pubmed/33924563
http://dx.doi.org/10.3390/cancers13081856
_version_ 1783683387866742784
author Yamazaki, Hideya
Suzuki, Gen
Masui, Koji
Aibe, Norihiro
Shimizu, Daisuke
Kimoto, Takuya
Yoshida, Ken
Nakamura, Satoaki
Okabe, Haruumi
author_facet Yamazaki, Hideya
Suzuki, Gen
Masui, Koji
Aibe, Norihiro
Shimizu, Daisuke
Kimoto, Takuya
Yoshida, Ken
Nakamura, Satoaki
Okabe, Haruumi
author_sort Yamazaki, Hideya
collection PubMed
description SIMPLE SUMMARY: Recently, high-risk prostate cancer was subdivided to a very-high-risk group considered to have the worst prognosis, including clinical stage T3b–T4, primary Gleason pattern 5, or more than four biopsy cores with Gleason score 8–10. Among these, T3b–T4 stage is a special interest in radiotherapy because of their wider target volume outside the prostate. We examined this subgroup and found that dose escalation in radiotherapy both with brachytherapy or intensity modulated radiotherapy (IMRT) improved biochemical free survival rate but not in prostate cancer specific survival rate and overall survival rate. ABSTRACT: To examine the efficacy of dose escalating radiotherapy into patients with cT3b or T4 localized prostate cancer, we compared Group A (86 conventional dose external beam radiotherapy: EBRT group, treated with 70–72 Gy) and group B (39 high dose EBRT group (HDEBRT group, 74–80 Gy) and 124 high-dose-rate brachytherapy (HDR) + EBRT (HDR boost)) using multi-institutional retrospective data. The actuarial 5-year biochemical disease-free survival (bDFS) rate, prostate cancer specific survival rate (PSS), and overall survival rate (OS) were 75.8%, 96.8%, and 93.5%. Group B showed superior 5-year bDFS rate (81.2%) as compared to the group A (66.5%) (p < 0.0001) with a hazard ratio of 0.397. Equivocal 5-year PSS (98.3% and 94.8% in group B and group A) and OS (both 93.7%) were found between those groups. Accumulated late grade ≥ 2 toxicities in gastrointestinal and genitourinary tracts were similar among those three groups. Therefore, both HDEBRT and HDR boost could be good options for improving the bDFS rate in cT3–T4 localized prostate cancer without affecting PSS and OS.
format Online
Article
Text
id pubmed-8070084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80700842021-04-26 Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy Yamazaki, Hideya Suzuki, Gen Masui, Koji Aibe, Norihiro Shimizu, Daisuke Kimoto, Takuya Yoshida, Ken Nakamura, Satoaki Okabe, Haruumi Cancers (Basel) Article SIMPLE SUMMARY: Recently, high-risk prostate cancer was subdivided to a very-high-risk group considered to have the worst prognosis, including clinical stage T3b–T4, primary Gleason pattern 5, or more than four biopsy cores with Gleason score 8–10. Among these, T3b–T4 stage is a special interest in radiotherapy because of their wider target volume outside the prostate. We examined this subgroup and found that dose escalation in radiotherapy both with brachytherapy or intensity modulated radiotherapy (IMRT) improved biochemical free survival rate but not in prostate cancer specific survival rate and overall survival rate. ABSTRACT: To examine the efficacy of dose escalating radiotherapy into patients with cT3b or T4 localized prostate cancer, we compared Group A (86 conventional dose external beam radiotherapy: EBRT group, treated with 70–72 Gy) and group B (39 high dose EBRT group (HDEBRT group, 74–80 Gy) and 124 high-dose-rate brachytherapy (HDR) + EBRT (HDR boost)) using multi-institutional retrospective data. The actuarial 5-year biochemical disease-free survival (bDFS) rate, prostate cancer specific survival rate (PSS), and overall survival rate (OS) were 75.8%, 96.8%, and 93.5%. Group B showed superior 5-year bDFS rate (81.2%) as compared to the group A (66.5%) (p < 0.0001) with a hazard ratio of 0.397. Equivocal 5-year PSS (98.3% and 94.8% in group B and group A) and OS (both 93.7%) were found between those groups. Accumulated late grade ≥ 2 toxicities in gastrointestinal and genitourinary tracts were similar among those three groups. Therefore, both HDEBRT and HDR boost could be good options for improving the bDFS rate in cT3–T4 localized prostate cancer without affecting PSS and OS. MDPI 2021-04-13 /pmc/articles/PMC8070084/ /pubmed/33924563 http://dx.doi.org/10.3390/cancers13081856 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamazaki, Hideya
Suzuki, Gen
Masui, Koji
Aibe, Norihiro
Shimizu, Daisuke
Kimoto, Takuya
Yoshida, Ken
Nakamura, Satoaki
Okabe, Haruumi
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title_full Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title_fullStr Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title_full_unstemmed Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title_short Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
title_sort radiotherapy for clinically localized t3b or t4 very-high-risk prostate cancer-role of dose escalation using high-dose-rate brachytherapy boost or high dose intensity modulated radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070084/
https://www.ncbi.nlm.nih.gov/pubmed/33924563
http://dx.doi.org/10.3390/cancers13081856
work_keys_str_mv AT yamazakihideya radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT suzukigen radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT masuikoji radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT aibenorihiro radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT shimizudaisuke radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT kimototakuya radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT yoshidaken radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT nakamurasatoaki radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy
AT okabeharuumi radiotherapyforclinicallylocalizedt3bort4veryhighriskprostatecancerroleofdoseescalationusinghighdoseratebrachytherapyboostorhighdoseintensitymodulatedradiotherapy